• The Washington Post reports that even as projections suggest that " the global cannabidiol (CBD) market will grow from $311.7 million this year to a staggering $1.25 billion by 2024," the US Food and Drug Administration (FDA) is attempting to apply the brakes.

"The U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing CBD, saying they had violated the Federal Food, Drug and Cosmetic Act," the Post writes. "At the same time, the FDA published a revised Consumer Update detailing broad safety concerns about CBD products.":

The critical message: "The federal government has not concluded that CBD is 'generally recognized as safe' (GRAS) for use in human or animal food. Thus, CBD in food and drink is still illegal."

The story notes that a number of manufacturers and retailers express frustration that federal regulators have been slow to provide guidance about what is legal and permissible, and what is not.

The Wall Street Journal notes that "the FDA has so far only approved one prescription drug containing CBD, a medication used to treat two rare forms of severe epilepsy. The agency said it is working to answer questions related to the safety and quality of other products containing CBD."